NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Douglas F. Kling Sells 51,043 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Douglas F. Kling sold 51,043 shares of the firm’s stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $21.10, for a total transaction of $1,077,007.30. Following the completion of the transaction, the chief operating officer directly owned 44,000 shares in the company, valued at approximately $928,400. The trade was a 53.71% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

NewAmsterdam Pharma Trading Up 1.3%

NewAmsterdam Pharma stock opened at $22.26 on Friday. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $27.29. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of -11.84 and a beta of -0.03. The firm has a 50 day simple moving average of $19.28 and a 200 day simple moving average of $20.25.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The company had revenue of $2.98 million for the quarter, compared to the consensus estimate of $1.46 million. On average, equities research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on NAMS shares. Needham & Company LLC reissued a “buy” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th. Cantor Fitzgerald started coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They set an “overweight” rating and a $42.00 price target for the company. Stifel Nicolaus started coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 10th. They set a “buy” rating and a $44.00 price target for the company. Finally, Citigroup started coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 17th. They set a “buy” rating and a $42.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.30.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds have recently made changes to their positions in NAMS. Deerfield Management Company L.P. Series C lifted its holdings in shares of NewAmsterdam Pharma by 378.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company’s stock worth $110,879,000 after acquiring an additional 3,412,590 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock worth $409,052,000 after purchasing an additional 3,061,224 shares during the last quarter. Wellington Management Group LLP lifted its stake in NewAmsterdam Pharma by 2,410.4% in the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company’s stock worth $59,499,000 after purchasing an additional 2,222,900 shares during the last quarter. Capital International Investors bought a new stake in NewAmsterdam Pharma in the fourth quarter worth $53,007,000. Finally, Alliancebernstein L.P. bought a new stake in NewAmsterdam Pharma in the fourth quarter worth $47,752,000. 89.89% of the stock is owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.